Stacy E. Croteau, MD, MMS
Medical Director, Boston Bleeding Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Image
Stacy E. Croteau, MD, MMS
Medical Director, Boston Bleeding Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Medical School
Brown University
2007
Providence
RI
Residency
Boston Combined Residency Program (BCRP)
2010
Boston
MA
Fellowship
Pediatric Hematology-Oncology
Boston Children's Hospital/Dana-Farber Cancer Institute
2014
Boston
MA
Certifications
American Board of Pediatrics (General)
American Board of Pediatrics (Hematology-Oncology)
Professional History
Dr. Stacy Croteau is a pediatric hematologist and clinical researcher at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, where she specializes in bleeding and clotting disorders. She completed her undergraduate and medical education at Brown University and then pursued training in Pediatrics and Pediatric Hematology/Oncology at Boston Children's Hospital and Dana-Farber Cancer Institute. Dr. Croteau joined the Boston Hemophilia Center as the associate director in 2014 and became the medical director in 2019. She enjoys clinical care of pediatric patients and leading research efforts to push the frontier of the quality and innovation in our current standards of medical practice.
Dr. Croteau currently serves at the primary investigator for several industry-sponsored and investigator initiated clinical trials and as the national chair of the American Thrombosis Hemostasis Network (ATHN)/National Hemophilia Program Coordinating Center (NHPCC) Transition Working Group. She also serves on the American Society of Hematology's Scientific Committee for Hemostasis. Her primary areas of academic interest are early drug development, advancing an approach for rationally designed personalized-prophylaxis regimens in hemophilia, and quality improvement efforts targeting patient transition from pediatric to adult care.
Publications
2025 Clinical Trials Update on Hemophilia, VWD, and Rare Inherited Bleeding Disorders. View Abstract
A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors. View Abstract
The eTHINK Study: Cognitive and Behavioral Outcomes in Children with Hemophilia. View Abstract
Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies. View Abstract
Corrigendum to 'Evaluation of Venous Thromboembolism Risk Factors Reveals Subtype Heterogenicity in Children with Central Venous Catheters: A Multi-Center Study from the CHAT Consortium' [Journal of Thrombosis and Haemostasis 21/9 (2023) 2441 - 2450]. View Abstract
Antithrombin lowering in hemophilia: a closer look at fitusiran. View Abstract
Evaluation of venous thromboembolism risk factors reveals subtype heterogenicity in children with central venous catheters: a multicenter study from the Children's Hospital Acquired Thrombosis consortium. View Abstract
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding. View Abstract
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. View Abstract
Hemophilia A/B. View Abstract
Kaposiform Lymphangiomatosis: Pathologic Aspects in 43 Patients. View Abstract
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remain. View Abstract
A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children's Hospital-Acquired Thrombosis Consortium. View Abstract
Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. View Abstract
Utility of Blood Cultures and Empiric Antibiotics in Febrile Pediatric Hemophilia Patients With Central Venous Access Devices. View Abstract
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. View Abstract
Symptomatic pulmonary embolus after catheter removal in children with catheter related thrombosis: A report from the CHAT Consortium. View Abstract
Phage display broadly identifies inhibitor-reactive regions in von Willebrand factor. View Abstract
The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B. View Abstract
Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency. View Abstract
Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. View Abstract
Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. View Abstract
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural). View Abstract
Discussing investigational AAV gene therapy with hemophilia patients: A guide. View Abstract
2021 clinical trials update: Innovations in hemophilia therapy. View Abstract
Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium. View Abstract
Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study. View Abstract
The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. View Abstract
Low von Willebrand factor in pediatric patients: Retrospective analysis of 293 cases informs diagnostic and therapeutic decision making. View Abstract
Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres. View Abstract
An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation. View Abstract
Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. View Abstract
Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. View Abstract
Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a survey of US patients with haemophilia and obesity (PwHO) and their partners and caregivers. View Abstract
Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream. View Abstract
Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users. View Abstract
Neuropsychological function in children with hemophilia: A review of the Hemophilia Growth and Development Study and introduction of the current eTHINK study. View Abstract
Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). View Abstract
Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. View Abstract
Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. View Abstract
Shifting Landscape of Hemophilia Therapy: Implications for Current Clinical Laboratory Coagulation Assays. View Abstract
Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. View Abstract
Evolving Complexity in Hemophilia Management. View Abstract
Focusing in on use of pharmacokinetic profiles in routine hemophilia care. View Abstract
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. View Abstract
Fifth Åland Island conference on von Willebrand disease. View Abstract
The spectrum of bleeding in women and girls with haemophilia B. View Abstract
Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism. View Abstract
Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor. View Abstract
2017 Clinical trials update: Innovations in hemophilia therapy. View Abstract
The clinical spectrum of kaposiform hemangioendothelioma and tufted angioma. View Abstract
Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. View Abstract
Center-Based Quality Initiative Targets Youth Preparedness for Medical Independence: HEMO-Milestones Tool in a Comprehensive Hemophilia Clinic Setting. View Abstract
Author's response: 'Transition considerations for extended half-life factor products'. View Abstract
Transition considerations for extended half-life factor products. View Abstract
Use of a fever fast track tool to reduce time to antibiotic dose in febrile pediatric oncology patients. View Abstract
Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centre-based pharmacy hit the mark? View Abstract
Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly. View Abstract
Novel dominant ß-thalassemia: Hb Boston-Kuwait [codon 139/140(+T)]. View Abstract
Resolving bony abnormality evolves to diffuse large B-cell lymphoma. View Abstract
Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. View Abstract